Stock vs Stock Comparison

Baxter International Inc. vs Abbott Laboratories

ABT wins the Tale of the Tape 6–2.

BAX$22.61
ABT$100.68

🏆 Tale of the Tape

26
BAXABT
-8.5%Profitability (Net Margin)14.7%
Valuation (P/E)27.7x
-1.0%Efficiency (ROIC)10.1%
5/9Health (Piotroski F)5/9
2.2Safety (Altman Z)4.9
5.7%Growth (Rev YoY)5.7%
-0.31Risk (Sharpe 1Y)-0.98
2.29xBalance Sheet (D/E)0.64x
1.68%FCF Yield4.18%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.316
252-Day Correlation
0.330
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricBAXABT
Market Cap$11.7B$175.4B
P/E Ratio27.7x
Forward P/E11.3x16.6x
P/B1.93x3.35x
Dividend Yield0.86%0.03%
Beta0.610.61

Quantitative Metrics

MetricBAXABT
DCF Fair Value$6.37$67.82
DCF Upside-71.8%-32.6%
Piotroski F5/95/9
Altman Z2.224.89
Beneish M-2.66-2.53
FCF Yield1.68%4.18%
Net Debt/EBITDA9.8x0.1x
ROIC-1.0%10.1%
WACC6.6%8.4%
ROIC – WACC-7.5pp1.7pp
Gross Margin30.0%56.4%
Net Margin-8.5%14.7%
Rev Growth YoY5.7%5.7%
Sharpe (1Y)-0.31-0.98
Max Drawdown 3Y
FCF Payout Ratio108%56%

BAX Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

BAX found in:

XHE1.77%
VBR0.23%
XLV0.21%
RSP0.19%
VHT0.16%
ONEY0.15%
VB0.13%
ONEV0.08%
VYM0.05%
SPYV0.04%
SCHV0.04%
VONV0.03%
IWD0.03%
IVV0.02%
VOO0.02%
SPLG0.02%
SPY0.02%
ITOT0.02%
SPTM0.02%
SCHX0.02%
SCHB0.02%
ONEO0.01%
URTH0.01%

ABT found in:

IHI16.93%
XLV2.94%
IYH2.64%
VHT2.33%
XHE1.71%
DGRW1.43%
NOBL1.34%
SDY1.07%
MGV0.75%
VIG0.69%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.59%
IWD0.58%
SPYV0.58%
VONV0.44%
IVV0.41%
QUS0.37%
SPLG0.37%
ESGV0.36%
ITOT0.36%
SCHX0.33%
SCHB0.30%
SPY0.27%
SPTM0.25%
VOO0.24%
URTH0.24%
VONE0.23%
VTI0.22%
ACWI0.16%
RSP0.16%
VT0.13%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

BAX vs ABT: Head-to-Head Analysis

Baxter International Inc. (BAX) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABT leads 6–2 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, BAX generates a return on invested capital (ROIC) of -1.0% compared to ABT's 10.1%. This suggests ABT is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between BAX and ABT is 0.316, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

BAX appears in 23 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, BAX or ABT?

Our quantitative analysis compares BAX and ABT across nine fundamental dimensions. ABT wins the Tale of the Tape 6–2. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are BAX and ABT correlated?

The 252-day correlation between BAX and ABT is 0.316. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.